MiNK Therapeutics, Inc.INKTEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Deep AnalysisCompare

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative invariant natural killer T (iNKT) cell therapies to treat cancer, autoimmune disorders and other serious unmet medical needs. It targets the global biopharmaceutical market, with core segments covering oncology and immunology, advancing its allogeneic cell therapy pipeline through preclinical and clinical trials.